USA flag logo/image

An Official Website of the United States Government

AN ANTIGEN-SPECIFIC IMMUNE DEVICE FOR MYASTHENIA GRAVIS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
13990
Program Year/Program:
1990 / SBIR
Agency Tracking Number:
13990
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Applied Immune Sciences, Inc.
5301 Patrick Henry Drive Santa Clara, CA 95054
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1990
Title: AN ANTIGEN-SPECIFIC IMMUNE DEVICE FOR MYASTHENIA GRAVIS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

ALTHOUGH MYASTHENIA GRAVIS (MG) IS THE BEST CHARACTERIZED HUMAN AUTOIMMUNE DISEASE, NO CURE IS AVAILABLE. ANTIBODIES TO NICOTINIC ACETYLCHOLINE RECEPTORS (ACHRS) OF MUSCLE ARE DETECTABLE IN 90 PERCENT OF PATIENTS AND CAUSE THE WEAKNESS OF MG. ANTIBODY LEVELS CAN BE DECREASED BY PLASMAPHERESIS, AND THIS IS CORRELATED WITH IMPROVED CLINICAL STATUS. THIS RESEARCH WILL ESTABLISH THE FEASIBILITY OF DEVELOPING AN ANTIGEN-SPECIFIC IMMUNOADSORPTION DEVICE TO REMOVE ANTI-ACHR IN MG. TOWARD THIS GOAL, APPLIED IMMUNESCIENCES, INC., HAS RECENTLY DESIGNED, CLONED, AND EXPRESSED THE MAJOREXTRACELLULAR DOMAIN (AMINO ACID RESIDUES 1-210) OF THE ALPHA SUBUNIT OF HUMAN ACHR. THE SPECIFIC AIMS ARE: (1) PURIFICATION OF RECOMBINANT ACHR (RACHR) FROM ESCHERICHIA COLI BY CONVENTIONAL AND AFFINITY CHROMATOGRAPHIC TECHNIQUES, (2) CHARACTERIZATION OF RACHR BY PHYSICAL AND BIOLOGICAL TECHNIQUES, (3) COVALENT IMMOBILIZATION OF RACHR ONTO CELLULOSIC MEMBRANES, AND (4) EVALUATION OF THE EFFICACY OF IMMOBILIZED RACHR FOR SPECIFIC REMOVAL OF PATHOLOGIC ANTIBODY FROM MG PATIENT SERAUSING A COMBINATION OF IMMUNOASSAYS. DEVELOPMENT OF AN ANTIGEN-SPECIFIC IMMUNOADSORPTION DEVICE REPRESENTS A SIGNIFICANT ADVANCE IN THE TREATMENT OF MG BECAUSE IT WILL ALLOW FOR THE SAFE AND EFFECTIVE REMOVAL OF MG PATIENT AUTOANTIBODIES. IN CONJUNCTION WITH SPECIFIC T-CELL THERAPY, THERE IS NOW HOPE FOR ANTIGEN-SPECIFIC IMMUNOMODULATIONS THAT MAY EVEN LEAD TO A LONG-TERM CURE.

Principal Investigator:

Sohel Talib
4153267302

Business Contact:

Small Business Information at Submission:

Applied Immunesciences Inc
200 Constitution Dr Menlo Park, CA 94025

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No